Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells
Molecular Biotechnology · 2025
DOI: 10.1007/s12033-024-01089-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biotechnology, 2025. Verfasst von Mahima Verma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences, Integral Centre of Excellence for Interdisciplinary Research (ICEIR), Integral University, Lucknow, India. Hauptthemen laut MEDLINE: Triterpenes, Apoptosis, Prostatic Neoplasms, Cell Proliferation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
Prostate cancer incidences are rising worldwide at an alarming rate. Drug resistance and relapse are two major challenges in the treatment of prostate cancer. Therefore, new multimodal, safe, and effective therapeutic agents are urgently required which could effectively mitigate the menace of tumor recurrence and chemo-resistance. Plant-derived products are increasingly being utilized due to their antioxidant, antibacterial, and anti-tumor potential. In the current study, 3-acetyl-11-keto-β-boswellic acid, a triterpenoid isolated from plant Boswellia, was utilized to ascertain its chemotherapeutic potential against human prostate cancer cells. Various in vitro assays including cell viability, nuclear staining, mitochondria potential, reactive oxygen species (ROS) generation, and quantification of apoptosis, were performed for the evaluation of the cytotoxic potential of AKBA. We observed that AKBA (10-50 µM) dose-dependently suppressed cell proliferation and caused programmed cell death in PC3 cells via both intrinsic and extrinsic pathway. Intriguingly, AKBA was also found to chemosensitize PC3 cells in synergistic combination with doxorubicin. To the best of our knowledge, this is the first study to document the synergistic chemosensitizing impact of AKBA when combined with doxorubicin in prostate cancer cells.This showcases the potential of AKBA in combinatorial therapy or adjuvant therapy for the management of prostate cancer. In sum, our results suggested that AKBA is a promising drug-like molecule against prostate cancer. Our investigation introduces a novel perspective, elucidating a previously unexplored dimension, and uncovering a compelling chemosensitizing phenomenon along with a strong synergistic effect arising from the concurrent application of these two agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biosciences, Integral Centre of Excellence for Interdisciplinary Research (ICEIR), Integral University, Lucknow, India.
- Department of Biology, College of Science, University of Hail, Hail, Saudi Arabia.
- Department of Biosciences, Integral University, Lucknow, India. ahmadirfan.amu@gmail.com.
Zitieren
APA
Verma, M., Fatima, S., Saeed, M., & Ansari, I. A. (2025). Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells. Molecular Biotechnology. https://doi.org/10.1007/s12033-024-01089-7
Vancouver
Verma M, Fatima S, Saeed M, Ansari IA. Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells. Molecular Biotechnology. 2025. doi:10.1007/s12033-024-01089-7
BibTeX
@article{Verma2025,
author = {Verma, Mahima and Fatima, Shireen and Saeed, Mohd and Ansari, Irfan Ahmad},
title = {Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells},
journal = {Molecular Biotechnology},
year = {2025},
doi = {10.1007/s12033-024-01089-7}
}
EUVIMED